Bicara Therapeutics Inc.
BCAX · XNASCIK 2023658fmd_158RHFF0VVFP87467B3DN62YF5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 31 | 64 | – |
| Total operating expenses | 40 | 82 | 156 |
| Operating income | (40) | (82) | (156) |
| Interest and investment income | 1 | 15 | 18 |
| Other non-operating income (expense) | (12) | 15 | 18 |
| Income before taxes | (52) | (68) | (138) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (52) | (68) | (138) |
| Net income | (52) | (68) | (138) |